- Home
- News
-
Boehringer Ingelheim licenses novel oral therapeutics program from Sitryx Therapeutics
Boehringer Ingelheim licenses novel oral therapeutics program from Sitryx Therapeutics
27 February 2026
Boehringer has acquired an exclusive license for a preclinical, small molecule program from Sitryx, a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory diseases, based at The Oxford Science Park.
The deal includes upfront and milestone payments to Sitryx totaling over US $500 million, plus tiered royalties.
The program offers a novel, oral, potentially disease-modifying treatment approach across multiple autoimmune and inflammatory disease indications.
The global burden of autoimmune and inflammatory diseases continues to rise sharply, with millions of patients unable to achieve sustainable disease control on existing therapies. This underscores the urgent need for novel, precise mechanisms that target disease‑driving pathways.
Carine Boustany, Head of Immunology and Respiratory Diseases Research at Boehringer Ingelheim, said:
“Autoimmune and inflammatory diseases remain areas where innovation is urgently needed. Sitryx’s small molecule inhibitor program brings forward a promising new mechanism that aligns with our focus on advancing first-in-class approaches. Together with Sitryx, we are committed to translating this science into therapies that can meaningfully improve patients’ lives.”
Iain Kilty, Chief Executive Officer of Sitryx, said:
“This collaboration is a major milestone for our company and is a clear validation of the strength of our pipeline and our expertise translating immunometabolic targets into meaningful therapeutic candidates. We are proud to out-license this preclinical program to Boehringer Ingelheim whose global capabilities in immunology and drug development will help position this program to deliver meaningful benefits to patients worldwide.”
Under the terms of the agreement, Sitryx grants Boehringer an exclusive global license to the multiple candidates and associated intellectual property within this small molecule inhibitor program. Boehringer assumes full responsibility for the program, including further research, clinical development and commercialization. Sitryx receives both upfront and near-term payments and is eligible to receive potential development, regulatory and commercialization milestone payments totaling more than $500 million, in addition to tiered royalties on future sales.
www.sitryx.com
www.boehringer-ingelheim.com
Read other news articles